-
Genocea Biosciences Spikes 30% After Positive Data From Phase 2 Trial
Thursday, March 31, 2016 - 10:11am | 217Shares of Genocea Biosciences Inc (NASDAQ: GNCA), a biopharmaceutical company that focuses on diseases with unmet needs, surged higher by more than 30 percent on Thursday. Genocea Biosciences announced earlier in the morning data from a 12-month Phase 2 study evaluating its lead candidate GEN...